AR103833A1 - Compuestos bicíclicos de sulfonamida cetona - Google Patents
Compuestos bicíclicos de sulfonamida cetonaInfo
- Publication number
- AR103833A1 AR103833A1 ARP160100551A ARP160100551A AR103833A1 AR 103833 A1 AR103833 A1 AR 103833A1 AR P160100551 A ARP160100551 A AR P160100551A AR P160100551 A ARP160100551 A AR P160100551A AR 103833 A1 AR103833 A1 AR 103833A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- haloalkyl
- heteroaryl
- independently selected
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Dermatology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Communicable Diseases (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Indole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), un enantiómero, diaestereómero, atropisómero del mismo, o una mezcla de los mismos, o una sal farmacéuticamente aceptable de los mismos, caracterizado porque el grupo de fórmula (2) es un compuesto seleccionado del grupo de fórmulas (3); R¹ es un arilo o heteroarilo de 5, 6, 7, 8, 9, ó 10 miembros, o un grupo cicloalquilo o heterocicloalquilo de 3, 4, 5, 6, 7, 8, 9, ó 10 miembros, en donde el grupo heteroarilo o heterocicloalquilo puede tener desde 1 hasta 3 heteroátomos seleccionados independientemente de O, N o S, o un átomo de carbono en el grupo cicloalquilo o heterocicloalquilo puede ser parte de un grupo C=O, y el grupo arilo, heteroarilo, cicloalquilo, o heterocicloalquilo está sustituido con 0, 1, 2, 3, ó 4 sustituyentes seleccionados independientemente de halo, -CN, -alquilo C₁₋₆, haloalquilo C₁₋₆, -OH, -O-alquilo C₁₋₆, -O-haloalquilo C₁₋₆, -C(=O)ORᵃ, o -(CRᵇRᵇ)ₙNRᵃRᵃ; R² es alquilo C₁₋₆, o un arilo o heteroarilo de 5, 6, 7, 8, 9, ó 10 miembros, o un grupo cicloalquilo o heterocicloalquilo de 3, 4, 5, 6, 7, 8, 9, ó 10 miembros, donde el grupo heteroarilo o heterocicloalquilo puede tener desde 1 hasta 3 heteroátomos seleccionados independientemente de O, N o S, o un átomo de carbono en el grupo cicloalquilo o heterocicloalquilo puede ser parte de un grupo C=O, y el grupo alquilo, arilo, heteroarilo, cicloalquilo o heterocicloalquilo está opcionalmente sustituido con desde 1 hasta 5 sustituyentes R⁶ seleccionados independientemente de halo, -CN, -alquilo C₁₋₆, haloalquilo C₁₋₆, -OH, -O-alquilo C₁₋₆, -O-haloalquilo C₁₋₆, -(CRᵇRᵇ)ₘ-A, -alquenilo C₂₋₆-A, -alquinilo C₂₋₆-A, o -O(CRᵇRᵇ)ₘ-A; cada R³ es seleccionado independientemente de H, -alquilo C₁₋₆, haloalquilo C₁₋₆, o halo; cada R⁴ es seleccionado independientemente de H, -alquilo C₁₋₆, haloalquilo C₁₋₆, o halo; cada R⁵ es seleccionado independientemente de H, -alquilo C₁₋₆, haloalquilo C₁₋₆, o halo; A es un grupo arilo, heteroarilo, o heterocicloalquilo de 4 hasta 9 miembros, o un grupo cicloalquilo de 3, 4, 5, 6, 7, 8, 9, ó 10 miembros, donde el grupo heteroarilo o heterocicloalquilo puede tener desde 1 hasta 3 heteroátomos seleccionados independientemente de O, N o S; y el grupo arilo, heteroarilo, heterocicloalquilo, o cicloalquilo está sustituido con 0, 1, 2, 3, ó 4 sustituyentes R⁷ seleccionados independientemente de halo, -NRᵃRᵃ, -alquilo C₁₋₆, -O-alquilo C₁₋₆, -(CRᵇRᵇ)ₘOH, hidroxialquilo C₁₋₆, haloalquilo C₁₋₆, -O-haloalquilo C₁₋₆, -CN, -C(=O)NRᵃRᵃ, -O-(CRᵇRᵇ)ₘB o -(CRᵇRᵇ)ₘB; B es un grupo arilo, heteroarilo, o heterocicloalquilo de 5 hasta 6 miembros, o un grupo cicloalquilo de 3 hasta 5 miembros, donde el grupo heteroarilo o heterocicloalquilo puede tener desde 1 hasta 3 heteroátomos seleccionados independientemente de O, N o S; y el grupo arilo, heteroarilo, cicloalquilo o heterocicloalquilo está sustituido con 0, 1, 2, 3, ó 4 sustituyentes R⁸ seleccionados independientemente de halo, -NRᵃRᵃ, -alquilo C₁₋₆, -O-alquilo C₁₋₆, hidroxialquilo C₁₋₆, -CF₃, -CHF₂, -CH₂F, -OCF₃, -OCHF₂, -OCH₂F, -CN o -C(=O)NRᵃRᵃ; cada Rᵃ es independientemente H, halo, -CN, -NRᶜRᶜ, -OH, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -O-haloalquilo C₁₋₆, o -O-alquilo C₁₋₆; cada Rᵇ es independientemente H, halo, -CN, -NRᶜRᶜ, -OH, -alquilo C₁₋₆, -haloalquilo C₁₋₆, -O-haloalquilo C₁₋₆, o -O-alquilo C₁₋₆; cada Rᶜ es independientemente H o -alquilo C₁₋₆; cada n es independientemente 0, 1, 2, 3 ó 4; y cada m es independientemente 0, 1, 2, 3 ó 4.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562127206P | 2015-03-02 | 2015-03-02 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR103833A1 true AR103833A1 (es) | 2017-06-07 |
Family
ID=55543087
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP160100551A AR103833A1 (es) | 2015-03-02 | 2016-03-02 | Compuestos bicíclicos de sulfonamida cetona |
Country Status (27)
Country | Link |
---|---|
US (1) | US10472356B2 (es) |
EP (1) | EP3265465B1 (es) |
JP (1) | JP6742331B2 (es) |
KR (1) | KR102649836B1 (es) |
CN (1) | CN107531705B (es) |
AR (1) | AR103833A1 (es) |
AU (1) | AU2016226340B2 (es) |
BR (1) | BR112017018755B1 (es) |
CA (1) | CA2978569C (es) |
CL (1) | CL2017002153A1 (es) |
CO (1) | CO2017009614A2 (es) |
CR (1) | CR20170392A (es) |
EA (1) | EA032928B1 (es) |
ES (1) | ES2728759T3 (es) |
HK (1) | HK1248687B (es) |
IL (1) | IL254161B (es) |
JO (1) | JO3595B1 (es) |
MX (1) | MX2017011042A (es) |
MY (1) | MY188700A (es) |
NZ (1) | NZ734888A (es) |
PE (1) | PE20180030A1 (es) |
PH (1) | PH12017501570B1 (es) |
SG (1) | SG11201707000UA (es) |
TN (1) | TN2017000376A1 (es) |
TW (1) | TWI700282B (es) |
UY (1) | UY36573A (es) |
WO (1) | WO2016141035A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10793550B2 (en) | 2017-03-24 | 2020-10-06 | Genentech, Inc. | 4-piperidin-n-(pyrimidin-4-yl)chroman-7-sulfonamide derivatives as sodium channel inhibitors |
CN107991409B (zh) * | 2017-11-28 | 2020-04-24 | 中国医学科学院肿瘤医院 | 采用高效合相色谱同时测定血浆中12种磺胺类药物的方法 |
EP3774801A1 (en) * | 2018-03-30 | 2021-02-17 | F. Hoffmann-La Roche AG | Fused ring hydro-pyrido compounds as sodium channel inhibitors |
WO2020199683A1 (zh) * | 2019-04-04 | 2020-10-08 | 上海海雁医药科技有限公司 | 氮杂环取代的磺酰基苯甲酰胺衍生物、其制法与医药上的用途 |
JP2021195367A (ja) * | 2020-06-10 | 2021-12-27 | アムジエン・インコーポレーテツド | シクロプロピルジヒドロキノリンスルホンアミド化合物 |
US11319960B2 (en) * | 2020-09-03 | 2022-05-03 | Shenzhen Lanhe Technologies Co., Ltd. | Portable temperature regulation device |
WO2022256676A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran analogs as modulators of sodium channels |
EP4347033A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Hydroxy and (halo)alkoxy substituted tetrahydrofurans as modulators of sodium channels |
WO2022256622A1 (en) | 2021-06-04 | 2022-12-08 | Vertex Pharmaceuticals Incorporated | N-(hydroxyalkyl (hetero)aryl) tetrahydrofuran carboxamides as modulators of sodium channels |
EP4347032A1 (en) | 2021-06-04 | 2024-04-10 | Vertex Pharmaceuticals Incorporated | Substituted tetrahydrofuran-2-carboxamides as modulators of sodium channels |
JP2024520649A (ja) | 2021-06-04 | 2024-05-24 | バーテックス ファーマシューティカルズ インコーポレイテッド | (2r,3s,4s,5r)-4-[[3-(3,4-ジフルオロ-2-メトキシ-フェニル)-4,5-ジメチル-5-(トリフルオロメチル)テトラヒドロフラン-2-カルボニル]アミノ]ピリジン-2-カルボキサミドを含む固体剤形及び投与レジメン |
CN117794919A (zh) | 2021-06-04 | 2024-03-29 | 沃泰克斯药物股份有限公司 | N-(羟烷基(杂)芳基)四氢呋喃甲酰胺类似物作为钠通道调节剂 |
WO2023205468A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205463A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
WO2023205465A1 (en) | 2022-04-22 | 2023-10-26 | Vertex Pharmaceuticals Incorporated | Heteroaryl compounds for the treatment of pain |
TW202408501A (zh) | 2022-04-22 | 2024-03-01 | 美商維泰克斯製藥公司 | 用於治療疼痛之雜芳基化合物 |
WO2024123815A1 (en) | 2022-12-06 | 2024-06-13 | Vertex Pharmaceuticals Incorporated | Process for the synthesis of substituted tetrahydrofuran modulators of sodium channels |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4620007A (en) * | 1980-09-03 | 1986-10-28 | Bayer Aktiengesellschaft | 6-fluoro-7-chloro-1-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid |
KR20060118398A (ko) | 2003-08-05 | 2006-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물 |
DE102004031850A1 (de) * | 2004-06-30 | 2006-01-26 | Sanofi-Aventis Deutschland Gmbh | Substituirte Tetrahydroisochinoline als MMP-Inhibitoren, Verfahren zu ihrer Herstellung und ihre Verwendung als Medikament |
WO2006106423A2 (en) | 2005-04-07 | 2006-10-12 | Pfizer Inc. | Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase |
EP2350091B1 (en) | 2008-10-17 | 2015-06-03 | Xenon Pharmaceuticals Inc. | Spiro-oxindole compounds and their use as therapeutic agents |
WO2011103715A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
KR20140095067A (ko) | 2011-10-28 | 2014-07-31 | 머크 샤프 앤드 돔 코포레이션 | 전압-게이팅 나트륨 채널에서의 선택적 활성을 갖는 벤족사졸리논 화합물 |
WO2013122897A1 (en) | 2012-02-13 | 2013-08-22 | Amgen Inc. | Dihydrobenzoxazine and tetrahydroquinoxaline sodium channel inhibitors |
US9051311B2 (en) | 2012-03-09 | 2015-06-09 | Amgen Inc. | Sulfamide sodium channel inhibitors |
US9776995B2 (en) | 2013-06-12 | 2017-10-03 | Amgen Inc. | Bicyclic sulfonamide compounds as sodium channel inhibitors |
-
2016
- 2016-03-02 JP JP2017546195A patent/JP6742331B2/ja active Active
- 2016-03-02 TN TNP/2017/000376A patent/TN2017000376A1/en unknown
- 2016-03-02 KR KR1020177027941A patent/KR102649836B1/ko active IP Right Grant
- 2016-03-02 PE PE2017001464A patent/PE20180030A1/es unknown
- 2016-03-02 BR BR112017018755-8A patent/BR112017018755B1/pt active IP Right Grant
- 2016-03-02 EP EP16710566.7A patent/EP3265465B1/en active Active
- 2016-03-02 EA EA201791941A patent/EA032928B1/ru not_active IP Right Cessation
- 2016-03-02 SG SG11201707000UA patent/SG11201707000UA/en unknown
- 2016-03-02 AU AU2016226340A patent/AU2016226340B2/en active Active
- 2016-03-02 CN CN201680024836.2A patent/CN107531705B/zh active Active
- 2016-03-02 MX MX2017011042A patent/MX2017011042A/es active IP Right Grant
- 2016-03-02 ES ES16710566T patent/ES2728759T3/es active Active
- 2016-03-02 JO JOP/2016/0032A patent/JO3595B1/ar active
- 2016-03-02 CA CA2978569A patent/CA2978569C/en active Active
- 2016-03-02 US US15/554,801 patent/US10472356B2/en active Active
- 2016-03-02 UY UY0001036573A patent/UY36573A/es unknown
- 2016-03-02 NZ NZ734888A patent/NZ734888A/en unknown
- 2016-03-02 MY MYPI2017001273A patent/MY188700A/en unknown
- 2016-03-02 CR CR20170392A patent/CR20170392A/es unknown
- 2016-03-02 TW TW105106422A patent/TWI700282B/zh active
- 2016-03-02 AR ARP160100551A patent/AR103833A1/es unknown
- 2016-03-02 WO PCT/US2016/020403 patent/WO2016141035A1/en active Application Filing
-
2017
- 2017-08-24 CL CL2017002153A patent/CL2017002153A1/es unknown
- 2017-08-27 IL IL254161A patent/IL254161B/en active IP Right Grant
- 2017-08-31 PH PH12017501570A patent/PH12017501570B1/en unknown
- 2017-09-22 CO CONC2017/0009614A patent/CO2017009614A2/es unknown
-
2018
- 2018-06-26 HK HK18108233.0A patent/HK1248687B/zh unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR103833A1 (es) | Compuestos bicíclicos de sulfonamida cetona | |
AR105845A1 (es) | Compuestos de heteroarilo bicíclicos fusionados como moduladores de la función irak4 | |
AR091193A1 (es) | HETEROCICLOS DE 5 MIEMBROS QUE CONTIENEN NITROGENO SUSTITUIDO POR CARBOXAMIDA O SULFONAMIDA COMO MODULADORES PARA EL RECEPTOR NUCLEAR HUERFANO RORg | |
AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
AR100438A1 (es) | Pirazolopiridinas y pirazolopirimidinas | |
AR089865A1 (es) | Derivados de bencimidazol e imidazopiridinas como moduladores de canales de sodio | |
AR104176A1 (es) | Inhibidores de ido (indolamina-2,3-dioxigenasa) | |
AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
AR108387A1 (es) | Compuestos de tipo tetrahidropirimidodiazepina y dihidropiridodiazepina para tratar el dolor y afecciones relacionadas con el dolor | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR103170A1 (es) | Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis | |
AR099177A1 (es) | Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1 | |
AR088423A1 (es) | Ligadores p1 ciclicos como inhibidores del factor xia | |
AR099228A1 (es) | Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos | |
AR105575A1 (es) | COMPUESTOS DE QUINOLINA COMO MODULADORES DE TNFa | |
AR087791A1 (es) | Derivados de benzofurano con sustitucion heterociclica y metodos para el uso de los mismos en el tratamiento de enfermedades virales | |
AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR099498A1 (es) | Compuestos de triazina y su uso farmacéutico | |
AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
AR116694A1 (es) | COMPUESTOS AGONISTAS b DEL RECEPTOR DE LA HORMONA TIROIDEA | |
AR108175A1 (es) | Compuestos antivíricos de tiazol acetamida | |
AR108864A1 (es) | Agentes antibacterianos | |
AR102222A1 (es) | Compuestos de indolinona, composiciones farmacéuticas que los comprende y usos de los mismos | |
AR102544A1 (es) | Compuestos derivados de dihidrohidantoína como herbicidas |